Influx Healthtech’s IPO subscription started on Wednesday, June 18, 2025, and will close on June 20, 2025, as per the schedule. The price band is set at ₹91 to ₹96 per share with a face value of ₹10.
Influx Healthtech IPO Subscription Status
Influx Healthtech IPO subscribed over 5.86x on its First day till 05.00 PM on 18th June 2025.
- Influx Healthtech IPO subscription QIB investors portion is 1.46x times, while NII subscribed 5.80x times, and RII investors subscribed 8.40x times.
- The company has received bids for 2,37,76,800 shares against 40,58,400 shares on offer on the First day.
- Influx Healthtech’s IPO subscribed over 5.86x times on day 1.
About Influx Healthtech IPO
Influx Healthtech Limited, founded in 2020, is a leading healthcare-focused company specializing in contract manufacturing. The company has built a strong reputation as a trusted Contract Development and Manufacturing Organization (CDMO), offering expert services to clients from various industries. The company comprises manufacturing units in Thane, Maharashtra, with areas of around 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft. The company is known to manufacture its products while keeping safety, quality, and compliance with regulations. Influx Healthcare works in different areas like dietary and nutritional supplements, cosmetics, ayurvedic/herbal products, veterinary feed supplements, and homecare items. The CDMO business caters to many major clients like Bling Brands, Pursuit of Wellness, Aarkios Health, HSHS Nutraceuticals Limited, Novus Life Science, Bruder Life Science, Fredun Pharmaceuticals, and BigFlex Lifescience. As of now, the company includes 165 permanent staff.
Influx Healthtech IPO Company Financial Report
The company reported revenue of ₹104.99 crores in 2025 against ₹100.10 crores in 2024. The company reported a profit of ₹13.37 crores in 2025 against a profit of ₹11.22 crores in 2024.
Influx Healthtech IPO GMP
Influx Healthtech’s IPO GMP was ₹40 as of Wednesday, 18th June. That indicates the IPO is trading at ₹136 with a ₹40 premium in the grey market against the issue price of ₹96.
